Abstract
Cancer is undoubtedly the number one killer in today's society. Traditional surgical treatment methods have their own limitations, especially in the treatment of end-stage or hematological tumors. Emerging immunotherapy is an unprecedented breakthrough technology in cancer treatment. For example, PD-1/PD-L1 and CAR-T immunotherapy. CAR-T has been proposed for many years, it is only in the last few years that it has been improved and applied in the clinic. Its effectiveness in the treatment of cancer in hematology is encouraging. For example, it has a great curative impact in the acute leukemia, in the field of non-Hodgkin lymphoma ,it is also recognized as one of the most prospective and developed tumor treatments. Clinical application of CAR-T has attracted extensive attention. This therapy is characterized by the ability to detect tumor-associated antigens preferentially detected by T cells, which has a significant anti-tumor effect. This article will focus on HCC, list the existing HCC CAR-T treatment targets and briefly describe associated clinical research.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
